GGrantIndex
← Search

Administration

$190,160P30FY2025CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

ADMINISTRATION: ABSTRACT Mayo Clinic Comprehensive Cancer Center (MCCCC) Administration partners with the enterprise Executive Director of MCCCC (Cheryl L. Willman, MD), Senior Leaders (Site Directors, Enterprise Deputy Directors, CCSG Component Leaders), Research Program (RP) Leaders, Shared Resource (SR) Directors, Disease Group Leaders, Clinical Research Leaders and members to advance the Center’s mission through innovative and effective administrative operations, data analytics, and novel research infrastructure. MCCCC is a single integrated matrix cancer center across the three Mayo Clinic Destination Medical Center sites with 363 members from 41 departments with 116 recruited in the last 5 years. MCCCC members hold $74.2M in annual direct cancer-relevant, peer-reviewed funding including $45.9M from NCI. MCCCC Administration is agile, experienced, collaborative and excels in leveraging the rigorous administrative team across three broad geographic locations: MCCCC in Rochester (MCR), Arizona (MCA), and Florida (MCF). Administration is exceptional in data analytics and tools to advance informed decision making, advancing scientific collaboration, facilities and technology planning, managing RPs and scientific retreats across three sites, internal Pilot Project competitions, Cancer Clinical Trials operations, Cancer Research Training and Education (CRTEC), Community Outreach and Engagement (COE), and compliance with all Mayo Clinic policies and federal and state requirements and regulations. Administration facilitates all internal and external strategic planning and evaluation efforts, partners with the Mayo Clinic Research Shield to develop and implement research administration policies and has shared oversight of SRs. Administration is responsible for internal and external communications and marketing, including social media and a new website, clinical research, and staffs the MCCCC Executive Committee, Senior Leadership Committee and other governance committees. Administration supports the Executive Director and Senior Leadership in faculty recruitment and professional development and retention. Administration has been a critical partner with Senior Leaders to advance the mission and new strategic initiatives during the last five years through support of the transformational enterprise-wide executive leadership structure and new enterprise-wide administrator elevated to the executive leadership of MC with 13 direct reports, responsible and accountable for the MCCCC across three sites, to lead and manage the MCCCC. This includes oversight and alignment of institutional commitment, strategic planning and evaluation efforts, and cancer clinical, research, and education programs which has culminated in the new 2030 Bold. Forward MCCCC Strategic Plan. Administration has been instrumental in facilitating the bi-directional priority setting process with site-specific Community Advisory Boards (CAB) to ratify Catchment Areas (CA) and identify priority cancers and cancer risk factors for each CA; leveraged new data science and visualization tools through implementation of EVAL, Velos and iLab; and launched the new MCCCC website and implemented communication strategies.

View original record on NIH RePORTER →